Edurant

Active Ingredient(s): Rilpivirine
FDA Approved: * May 20, 2011
Pharm Company: * TIBOTEC
Category: HIV / AIDS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Edurant Overview

Rilpivirine (TMC278, trade name Edurant) is a pharmaceutical drug, developed by Tibotec, for the treatment of HIV infection.[1][2] It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz.[3][4] Rilpivirine entered phase III clinical trials in April 2008,[5][6]...

Read more Edurant Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Rilpivirine

Recent Edurant Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Rilpivirine
  • Tablet: 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Edurant: (1 result)

Sorted by National Drug Code
  • 59676-278 Edurant 25 mg Oral Tablet by Janssen Products, Lp

Other drugs which contain Rilpivirine or a similar ingredient: (7 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 19 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA